US PRE-MARKET MOVERS: AZN, CIBR, U, AGX, TRIP
ES -0.4% NQ -0.6% RTY -0.6%
- AZN +3.6%: Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials
- CIBR -2.4%: Reports emerge of leaked Anthropic AI model, "Claude Mythos"; co. believes it poses unprecedented cybersecurity risks
- U +14.1%: Raised Q1 revenue view; PT raised at BofA
- AGX +9.5%: Earnings beat; upgraded at JPM to 'Overweight' from 'Neutral'
- TRIP +3.8%: Upgraded at BofA to 'Buy' from 'Neutral'
Context
In pre-market trading, AstraZeneca (AZN) is up 3.6% after positive trial results, which may signal a strong outlook for their pipeline. Meanwhile, U is seeing a significant gain of 14.1% following an upward revision of revenue guidance, highlighting bullish sentiment around its growth prospects. The upgrades of AGX and TRIP at BofA indicate increased confidence in their future performance, likely leading to improved investor sentiment in the broader sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#AZN#UNITED KINGDOM#EUROPE#JPMORGAN CHASE & CO#ASTRAZENECA PLC#3I GROUP PLC#EQUITIES#EU SESSION#US SESSION#HIGHLIGHTED#RESEARCH SHEET#PHARMACEUTICALS#DIVERSIFIED BANKS#ASSET MANAGEMENT & CUSTODY BANKS#ELECTRIC UTILITIES#PHARMACEUTICALS (GROUP)#BANKS#CAPITAL MARKETS#ELECTRIC UTILITIES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#FINANCIAL SERVICES#UTILITIES (GROUP)#S&P 500 INDEX#NASDAQ 100 INDEX#FTSE 100 INDEX#EVERSOURCE ENERGY#ES#JPM#III#ARTIFICIAL INTELLIGENCE#US PRE-MARKET#US RESEARCH#US EQUITIES